Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045
MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases,…